Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 253

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 7
Chunk 253
---
 Loss from operations

    (7,975,109
    )

    (8,656,664
    )

    681,555

    Total other (expense) income, net

    (7,063,427
    )

    8,536,410

    (15,599,837
    )

    Net loss
     
    $
    (15,038,536
    )
     
    $
    (120,254
    )
     
    $
    (14,918,282
    )

Research and Development Expenses

The following table summarizes our research and development expenses for the periods presented:

    Year EndedDecember 31,

    2024

    2023

    Change

    GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses
     
    $
    1,681,731

    $
    209,702

    $
    1,472,029

    Manufacturing expenses

    390,022

    697,429

    (307,407
    )

    Other program expenses

    77,679

    2,190,493

    (2,112,814
    )

    Other expenses

    172,369

    282,948

    (110,579
    )

    Personnel expenses (including stock-based compensation)

    1,227,195

    765,330

    461,865

    Total research and development expenses
     
    $
    3,548,996

    $
    4,145,902

    $
    (596,906
    )

Research and development expenses decreased by $0.6 million, from $4.1 million for the year ended December 31, 2023 to $3.5 million for the year ended December 31, 2024. The decrease was primarily due to decreases of $2.1 million in other program expenses and $0.3 million in manufacturing expenses, offset by increases of $1.5 million in clinical study expenses related to GEM-AKI, GEM-CKD and GEM-PSI and $0.5 million in personnel expenses. Other program expenses include pre-clinical costs and clinical preparation costs primarily for programs GEM-AKI, GEM-CKD and GEM-PSI.

 64

General and Administrative Expenses

The following table summarizes our general and administrative expenses